1[1]Sasaki T,Maeda Y,Kobayashi T,et al.Standard chemotherapy for gastrointestinal malignancies based on evidence.Jap J Cancer Chemother,2000,27 (20):166
2[4]Jin M,Shen L,Hu B,et al.Mature data on capecitabine (X) + fractionated cisplatin (P) as first-line therapy in patients (pts) with advanced gastric carcinoma (AGC).Proc Am Soc Clin Oncol,2006,24:196S
3[5]Kang Y,Kang WK,Shin DB,et al.Randomized phase Ⅲtrial of capecitabine/cisplatin (XP) vs continuous infusion of 5 -FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):Efficacy and safety results.Proc Am Soc Clin Oncol,2006,24:183S
4[6]Shitara K,Sakata Y,Kudou T,et al.Gastric Cancer:S -1 monotherapy and its progress.Jpn J Cancer Chemother,2006,33 (Suppl I):43
5[7]Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric or gastroesophageal adenocarcinoma.J Clin Oncol,2005,23 (24):5660
6[9]Cunningham D,Rao S,Starling N,et al.Randomised multicentie phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patientswith advanced oesophagogastric cancer:The REAL 2 trial.Proc Am Soc Clin Oncol,2006,24:182S
7[10]Park Y,Lee J,Ryoo B,et al.Aphase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.Proc Am Soc Clin Oncol,2006,24:197S
8[11]Pozzo C,Bugat R,Peschel C,et al.Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastrooesophagealjunction adenocarcin oma:Final results of a randomized phase Ⅱ study.Proc Am Soc Clin Oncol,2000,20:531
9[12]Bouche O,Raoul J,Giovanini M,et al.Randomized phase Ⅱ trial of LV5FU2,LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA):Final results of study FFCD9803,Proc Am Soc Clin Oncol,2003,21,1033
10[13]Lee J,Kang W,Lee S,et al.A phase Ⅱ study of irinotecan,oxaliplatin,5-fluorouracil,leucovorin (FOLFOXIRI) as a first-line chemotherapy in metastatic gastric cancer.Proc Am Soc Clin Oncol,2006,24
二级参考文献9
1Cocconi G, Carlini P, Gamboni A, et al. Cisplatin, eprubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubic and methotrexate (FAMTX) in advanced gastric carcinoma[J]. Ann Oncol, 2003, 14(8): 1258 - 1263.
2Dickson JL, Cunningham D. Systemic treatment of gastric cancer[J]. Eur J Gastroenterol Hepatol, 2004, 16(3): 255-263.
3Aitini E, Rabbi C, Mambrini A, et al. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience[J]. Tumori,2001, 87(1): 20-24.
4Kubota T. Theoretical basis for low-dose CDDP/5-FU therapy[J]. Jpn J Cancer Chemother, 1999, 26(11): 1536 - 1541.
5WatersJS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplathl and fluorouracil for gastric cancer: results of a randomized trial [J]. Br J Cancer. 1999, 80 (1-2): 269-272.
6Webb A, Cmmingham D, Scarffe JH. et al. Randomized trial comparing epirubicm, cisplatin and fluorouracil versus fluerouracil, doxorubicin and methotrexate in advanced esophagogastric cancer[J].J Clin Oncol, 1997, 15(1): 261 -267.
